Evotec Biologics Moves U.S. War Dept. Antibody JST-018 to Phase 1
Image
Seattle – September 12, 2026 -- Just – Evotec Biologics has initiated a first-in-human Phase 1 clinical trial for JST-018, a monoclonal antibody cocktail targeting orthopoxviruses, developed under a U.S. Department of War contract.
Just – Evotec Biologics advanced JST-018 from sequence selection to clinical trial under a 2023 Department of War contract
The biologics CDMO, a wholly owned subsidiary of Evotec SE (NASDAQ: EVO; Frankfurt: EVT), executed the full development chain — preclinical work, process development, regulatory submission and cGMP manufacturing of clinical trial material — at its J.POD® facility in Redmond, Washington, using its continuous bioprocessing platform.